Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ribosomal protein S24 pseudogene 17 (RPS24P17) is a human pseudogene related to the ribosomal protein S24 gene family. Unlike active genes, pseudogenes are typically nonfunctional remnants or copies of genes that have lost their capacity to encode proteins due to mutations or lack of regulatory sequences. RPS24P17 does not participate in ribosome structure or function and is not considered a therapeutic target. Multiple pseudogenes for ribosomal protein genes exist throughout the genome; their biological roles, if any, are generally unclear and not directly relevant to drug action or disease mechanisms[4][8][9].\n\nKey contextual clarification:\n- The functional ribosomal protein S24 (RPS24)—not its pseudogene—has clinical importance in diseases like Diamond-Blackfan anemia, but this does not apply to the RPS24P17 pseudogene[3][5][7].\n- Pseudogenes like RPS24P17 are not targeted by drugs, do not encode functional receptors or enzymes, and have no described therapeutic or biomarker relevance[8][9].\n\nIf you have mistakenly targeted RPS24P17 as a therapeutic target, you should instead refer to the functional RPS24 gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein S24 pseudogene 17 (RPS24P17).